Ruifeng Xu, PhD
Ruifeng Xu, PhD
Biometrician
Merck & Co., Inc.
One Merck Drive
Whitehouse Station,
NJ
USA
08889
Papers:
450 - Poster Session B
Model prediction of mean PFS and OS time from a phase II trial comparing vintafolide plus pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer patients with 100% folate receptor–positive target